GlassScriptPhysician profile
Michelle Tull
NPI 1073066023
$1,006.95
in general payments reported to CMS, 2019-2025
21 companies · $887 in 2025
The $887 reported for 2025 was more than what 82% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.00 · 2024: $25.43 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $152.60 | 2025 | Fruzaqla, Hyqvia |
| Pfizer INC. | $145.06 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $122.19 | 2025 | Libtayo |
| Sanofi-Aventis U.S. LLC | $95.00 | 2022 | |
| Abbvie INC. | $62.56 | 2025 | |
| Janssen Biotech, INC. | $55.13 | 2025 | Rybrevant, Carvykti |
| Lundbeck LLC | $40.60 | 2024-2025 | Vyepti |
| Genzyme Corporation | $36.75 | 2025 | |
| Adaptive Biotechnologies Corporation | $34.57 | 2025 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $31.50 | 2025 | |
| Tersera Therapeutics LLC | $31.45 | 2025 | Zoladex |
| Pharmacosmos Therapeutics INC. | $26.60 | 2025 | Monoferric |
| Secura Bio, INC. | $25.95 | 2025 | Copiktra |
| Stemline Therapeutics INC. | $21.46 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $21.25 | 2025 | Enhertu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $20.98 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $19.05 | 2025 | |
| Rigel Pharmaceuticals, INC. | $17.73 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Agios Pharmaceuticals, INC. | $17.22 | 2025 | Pyrukynd |
| Incyte Corporation | $15.38 | 2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $13.92 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Tull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.